169 related articles for article (PubMed ID: 12057062)
41. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
[TBL] [Abstract][Full Text] [Related]
42. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
[TBL] [Abstract][Full Text] [Related]
43. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.
Woods WG; Barnard DR; Alonzo TA; Buckley JD; Kobrinsky N; Arthur DC; Sanders J; Neudorf S; Gold S; Lange BJ
J Clin Oncol; 2002 Jan; 20(2):434-40. PubMed ID: 11786571
[TBL] [Abstract][Full Text] [Related]
44. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
46. Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes.
Hast R; Eriksson M; Jakovleva K
Pol Arch Med Wewn; 1998 Feb; 99(2):144-9. PubMed ID: 9686516
[No Abstract] [Full Text] [Related]
47. The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.
Kako S; Kanda Y; Kato J; Yamamoto W; Kato S; Onizuka M; Yokota A; Tatara R; Yokoyama H; Hagihara M; Usuki K; Gotoh M; Watanabe R; Kawai N; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Hematol Oncol; 2017 Sep; 35(3):341-349. PubMed ID: 26643559
[TBL] [Abstract][Full Text] [Related]
48. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
[TBL] [Abstract][Full Text] [Related]
49. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups.
Oosterveld M; Wittebol SH; Lemmens WA; Kiemeney BA; Catik A; Muus P; Schattenberg AV; de Witte TJ
Br J Haematol; 2003 Oct; 123(1):81-9. PubMed ID: 14510946
[TBL] [Abstract][Full Text] [Related]
50. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
51. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Ruutu T; Hänninen A; Järventie G; Koistinen P; Koivunen E; Kätkä K; Nousiainen T; Oksanen K; Pelliniemi TT; Remes K; Timonen T; Volin L; Elonen E
Leuk Res; 1997 Feb; 21(2):133-8. PubMed ID: 9112430
[TBL] [Abstract][Full Text] [Related]
52. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
53. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
54. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
55. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
56. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
57. [Current approaches of treatment for myelodysplastic syndrome (MDS)].
Lewandowski K; Goździk J; Hansz J
Acta Haematol Pol; 1995; 26(4):333-41. PubMed ID: 8571734
[TBL] [Abstract][Full Text] [Related]
58. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
59. [The myelodysplastic syndrome II. New therapeutic principles, course and prognosis].
Hasselbalch HC; Juhl BR; Hansen PB
Ugeskr Laeger; 2002 Jan; 164(4):479-82. PubMed ID: 11838418
[TBL] [Abstract][Full Text] [Related]
60. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]